Extreme heat can force the heart to pump harder and faster as the body struggles to cool itself down. Doctors warn that soaring temperatures increase cardiovascular strain, raising the risk of dehydration, blood clots and electrolyte imbalances — especially for people with pre-existing heart conditions and vulnerable populations during heatwaves.

Extreme Heat Puts Dangerous Stress On Your Heart, Doctors Warn

Standing desks were introduced in some workplaces not so long ago to address health issues associated with long hours of sitting. But now a large study has found that these design innovations cannot solve heart problems or stroke risk. Long hours of standing could even lead to more health troubles like vein swelling and blood clots in the legs.

The Sydney University study reached this conclusion after examining data of 83,013 adults in the Biobank health records database of the UK.

Watch: 75% employees already using AI at work: Report

<div class="ui-state-default" contenteditable="false">
<div class="twitter-block" draggable="false">
<div class="videoWrapper trancodeVideo"><iframe allowfullscreen="" autoplay="1" class="includeVideo" frameborder="0" height="350" src="https://www.wionews.com/videos/75-employees-already-using-ai-at-work-report-719593/embed" style="width:100%;max-width:560px;" width="560"></iframe></div>
</div>
<a class="close-mark close-div" href="#" id="jqclosemark">×</a></div>

 
Standing for extended periods may fail to address health issues linked to long hours of sitting, it found.

On the other hand, standing could raise the possibility of circulator issues like deep vein thrombosis and varicose veins, said&nbsp;the study published in the International Journal of Epidemiology.

It found no significant reduction in heart disease risks in long hours of standing.&nbsp; 
&nbsp; 
For every extra 30 minutes spent standing beyond two hours, the risk of circulatory disease rises by 11 per cent, according to the study.&nbsp;

<a href="https://www.wionews.com/india-news/bajajs-employee-dies-by-suicide-hold-work-pressure-and-no-sleep-for-45-days-responsible-for-his-actions-763254">Also read: Bajaj employee dies by suicide, cites ‘work pressure’ and ‘no sleep for 45 days’ for his extreme step</a>

“The key takeaway is that standing for too long will not offset an otherwise sedentary lifestyle and could be risky for some people in terms of circulatory health. We found that standing more does not improve cardiovascular health over the long-term and increases the risk of circulatory issues,” The Guardian quoted Dr Matthew Ahmadi, the study's lead author, as saying.&nbsp;

<h2>So what's the way out?</h2>

Regular movement through the day is important, according to the study.

Maintaining an active lifestyle is key to&nbsp;reducing disease risk. 
Whether sitting or standing, one should avoid prolonged periods of inactivity.

<a href="https://www.wionews.com/entertainment/lifestyle/news-no-more-9-to-5-employees-are-now-unofficially-changing-work-hours-to-10-to-4-data-shows-758369">Also read: No more 9 to 5: Employees are now unofficially changing work hours to 10 to 4, data shows</a> 
 
“Take regular breaks, walk around, go for a walking meeting, use the stairs, take regular breaks when driving long distances, or use that lunch hour to get away from the desk and do some movement,” said Emmanuel Stamatakis, the director of the Mackenzie Wearables Research Hub at the University of Sydney.

Incorporating movement and structured exercise is a more effective strategy for reducing cardiovascular disease risk, Stamatakis said as quoted by The Guardian.

Emily McGrath at the British Heart Foundation said the study showed the importance of being active during the working day.

"The more people can avoid being stationary, the better...it is important to get active to reduce this risk,” the paper quoted her as saying. 
 
(With inputs from agencies)

Standing desks were introduced in some workplaces not so long ago to address health issues associated with long hours of sitting. But now a large study has found that these design innovations cannot solve heart problems or stroke risk.

Standing desks were introduced in some workplaces not so long ago to address health issues associated with long hours of sitting. But now a large study has found that these design innovations cannot solve heart problems or stroke risk. Long hours of standing could even lead to more health troubles like vein swelling and blood clots in the legs. The Sydney University study reached this conclusion after examining data of 83,013 adults in the Biobank health records database of the UK. Watch: 75% employees already using AI at work: Report × Standing for extended periods may fail to address health issues linked to long hours of sitting, it found. On the other hand, standing could raise the possibility of circulator issues like deep vein thrombosis and varicose veins, said the study published in the International Journal of Epidemiology. It found no significant reduction in heart disease risks in long hours of standing. For every extra 30 minutes spent standing beyond two hours, the risk of circulatory disease rises by 11 per cent, according to the study. Also read: Bajaj employee dies by suicide, cites ‘work pressure’ and ‘no sleep for 45 days’ for his extreme step “The key takeaway is that standing for too long will not offset an otherwise sedentary lifestyle and could be risky for some people in terms of circulatory health. We found that standing more does not improve cardiovascular health over the long-term and increases the risk of circulatory issues,” The Guardian quoted Dr Matthew Ahmadi, the study's lead author, as saying. So what's the way out? Regular movement through the day is important, according to the study. Maintaining an active lifestyle is key to reducing disease risk. Whether sitting or standing, one should avoid prolonged periods of inactivity. Also read: No more 9 to 5: Employees are now unofficially changing work hours to 10 to 4, data shows “Take regular breaks, walk around, go for a walking meeting, use the stairs, take regular breaks when driving long distances, or use that lunch hour to get away from the desk and do some movement,” said Emmanuel Stamatakis, the director of the Mackenzie Wearables Research Hub at the University of Sydney. Incorporating movement and structured exercise is a more effective strategy for reducing cardiovascular disease risk, Stamatakis said as quoted by The Guardian. Emily McGrath at the British Heart Foundation said the study showed the importance of being active during the working day. "The more people can avoid being stationary, the better...it is important to get active to reduce this risk,” the paper quoted her as saying. (With inputs from agencies)

Standing desks were once touted as beneficial for health. New study says they could add to problems

A recent study conducted by Chinese researchers discovered microplastics in blood clots surgically removed from arteries in the heart and brain, as well as deep veins in the lower legs.

The journal eBioMedicine published the research, which involved thirty participants.&nbsp;The Chinese researchers also discovered a possible correlation between the amount of microplastics in blood clots and the severity of the condition, much like a prior study involving 257 patients which&nbsp;discovered that the presence of microplastics in plaques increased&nbsp;risk of heart attack or stroke.

The research included thirty patients who had suffered from heart attacks, strokes, or deep vein thrombosis, a disorder in which clots develop in deep veins, usually in the legs or pelvis, and required surgery to remove the blood clots.

Patients averaged 65 years old and had a variety of health histories and behaviors, including smoking, alcohol usage, high blood pressure, and diabetes. They utilised plastic items on a daily basis and were about evenly distributed across rural and urban locations.

Chemical examination revealed microplastics of varied shapes and sizes in 24 of the 30 blood clots tested, with variable amounts.

Also read:&nbsp;<a href="https://www.wionews.com/science/video-showing-head-transplants-on-brain-dead-bodies-using-ai-shocks-netizens-724686">Video showing head transplants on brain-dead bodies using AI shocks netizens</a>

The same plastics that were found in the Italian-led research of artery plaques were also found during testing: polyvinyl chloride (PVC), which is frequently used in construction, and polyethylene (PE), which is commonly used in bottles and shopping bags.&nbsp;

The clots were found to include polyamide 66, a common plastic used in textiles and fabric, according to the recent study. PE accounted for 54% of the tested particles, making it the most prevalent plastic of the 15 kinds discovered by the research.

The researchers hypothesized that microplastics might somehow be clumping together in blood to worsen clotting because they also discovered that patients with higher levels of microplastics in their blood clots also had higher D-dimer levels than patients without microplastics found in thrombi.

Further research is necessary to fully understand this, though, as this study only looked at potential linkages rather than causes because it did not assess the amount of microplastics in the blood of the patients.

&nbsp;"These findings suggest that microplastics may serve as a potential risk factor associated with vascular health. Future research with a larger sample size is urgently needed to identify the sources of exposure and validate the observed trends in the study," the scientists wrote.

(With inputs from agencies)

A recent study conducted by Chinese researchers discovered microplastics in blood clots surgically removed from arteries in the heart and brain, as well as deep veins in the lower legs.

A recent study conducted by Chinese researchers discovered microplastics in blood clots surgically removed from arteries in the heart and brain, as well as deep veins in the lower legs. The journal eBioMedicine published the research, which involved thirty participants. The Chinese researchers also discovered a possible correlation between the amount of microplastics in blood clots and the severity of the condition, much like a prior study involving 257 patients which discovered that the presence of microplastics in plaques increased risk of heart attack or stroke. The research included thirty patients who had suffered from heart attacks, strokes, or deep vein thrombosis, a disorder in which clots develop in deep veins, usually in the legs or pelvis, and required surgery to remove the blood clots. Patients averaged 65 years old and had a variety of health histories and behaviors, including smoking, alcohol usage, high blood pressure, and diabetes. They utilised plastic items on a daily basis and were about evenly distributed across rural and urban locations. Chemical examination revealed microplastics of varied shapes and sizes in 24 of the 30 blood clots tested, with variable amounts. Also read: Video showing head transplants on brain-dead bodies using AI shocks netizens The same plastics that were found in the Italian-led research of artery plaques were also found during testing: polyvinyl chloride (PVC), which is frequently used in construction, and polyethylene (PE), which is commonly used in bottles and shopping bags. The clots were found to include polyamide 66, a common plastic used in textiles and fabric, according to the recent study. PE accounted for 54% of the tested particles, making it the most prevalent plastic of the 15 kinds discovered by the research. The researchers hypothesized that microplastics might somehow be clumping together in blood to worsen clotting because they also discovered that patients with higher levels of microplastics in their blood clots also had higher D-dimer levels than patients without microplastics found in thrombi. Further research is necessary to fully understand this, though, as this study only looked at potential linkages rather than causes because it did not assess the amount of microplastics in the blood of the patients. "These findings suggest that microplastics may serve as a potential risk factor associated with vascular health. Future research with a larger sample size is urgently needed to identify the sources of exposure and validate the observed trends in the study," the scientists wrote. (With inputs from agencies)

Microplastics found in blood clots linked to heart attacks and strokes

After <a href="https://www.wionews.com/world/australia-deputy-pm-fined-for-not-wearing-mask-in-breach-of-covid-19-rules-394628">Australian </a>PM Scott Morrison allowed citizens under 40 to get the AstraZeneca vaccine several state governments resisted the central governments&nbsp;call to vaccinate people.

Watch:

<div class="videoWrapper trancodeVideo"><iframe allowfullscreen="" autoplay="1" class="includeVideo" frameborder="0" height="350" src="https://www.wionews.com/videos/australia-sydney-extends-covid-lockdown-to-entire-city-394514/embed" style="width:100%;max-width:560px;" width="560"></iframe></div>

The country's health minister Greg Hunt said that "COVID-19 vaccine AstraZeneca can be used in adults aged under 60 years of age for whom Pfizer is not available," while adding, "The benefits are likely to outweigh the risks for that individual."

<div class="ui-state-default" contenteditable="false">
<div class="twitter-block" draggable="false">
<blockquote class="twitter-tweet">
Thank you Ken and each and every Australian who has received a COVID-19 vaccination. Getting a COVID-19 vaccine protects you &amp; your community. <a href="https://t.co/JjYp9GOJIh">https://t.co/JjYp9GOJIh</a>
— Greg Hunt (@GregHuntMP) <a href="https://twitter.com/GregHuntMP/status/1407161029042204672?ref_src=twsrc%5Etfw">June 22, 2021</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
<a class="close-mark close-div" href="#" id="jqclosemark">×</a></div>

However, <a href="https://www.wionews.com/world/australias-covid-19-response-team-holds-urgent-meeting-amid-new-outbreaks-394361">Western Australia's</a> premier Mark McGowan on giving access to those under 40, said: "That shouldn’t happen. Clearly, we get different advice, I suppose, or have a different approach."

<div class="ui-state-default" contenteditable="false">
<div class="twitter-block" draggable="false">
<blockquote class="twitter-tweet">
Australia has now passed 7 million doses of COVID-19 vaccine administered. 
 
Thank you to each and every Australian who has come forward for their vaccination. You are helping to save lives and protect lives. <a href="https://t.co/nZFvwd0lND">pic.twitter.com/nZFvwd0lND</a>
— Greg Hunt (@GregHuntMP) <a href="https://twitter.com/GregHuntMP/status/1408259579239145474?ref_src=twsrc%5Etfw">June 25, 2021</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
<a class="close-mark close-div" href="#" id="jqclosemark">×</a></div>

The hesitancy over AstraZeneca shots is linked to reports of blood clots even as the World Health Organization(WHO) recommended continued use of the AstraZeneca shot asserting that benefits outweighed the rare risk of clots.&nbsp;

"Now the ATAGI (Australian Technical Advisory Group on Immunisation) advice talks about a preference for AstraZeneca to be available, made available to those as preferred for those over 60," the Australian PM had said.

"But the advice does not preclude persons under 60 from getting the AstraZeneca vaccine," Morrison added.

Morrison had said that all under-60s should “go and have that discussion with your GP” over AstraZeneca vaccine shots. Australia’s High Commissioner to India, Barry O’Farrell took the second shot of the AstraZeneca(Covishield) while saying on Twitter,&nbsp;"thought it fitting to wear my NSW Blues jersey."

<div class="ui-state-default" contenteditable="false">
<div class="twitter-block" draggable="false">
<blockquote class="twitter-tweet">
Second Astra Zeneca shot (Covishield) courtesy of the Govt of India 🇮🇳. Thought it fitting to wear my ⁦<a href="https://twitter.com/NSWBlues?ref_src=twsrc%5Etfw">@NSWBlues</a>⁩ jersey <a href="https://twitter.com/hashtag/TwoWinsTwoShots?src=hash&amp;ref_src=twsrc%5Etfw">#TwoWinsTwoShots</a>. <a href="https://t.co/yZR7Z2cx5b">pic.twitter.com/yZR7Z2cx5b</a>
— Barry O'Farrell (@barryofarrell) <a href="https://twitter.com/barryofarrell/status/1409753165763809292?ref_src=twsrc%5Etfw">June 29, 2021</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
<a class="close-mark close-div" href="#" id="jqclosemark">×</a></div>

The Australian PM had said that the <a href="https://www.wionews.com/world/moderna-shares-soar-after-report-that-its-covid-shot-works-against-delta-variant-394882">Delta variant </a>was proving "to be a far more difficult element" and presenting "very different challenges".

Several million Australians are in various forms of lockdown amid a slow vaccine rollout. Morrison said young people can take the vaccine after talking to the doctor who will be covered by a no-fault indemnity scheme.

Amid the vaccine row, Northern Queensland state along with the Western Australian capital of Perth announced lockdowns to combat the fast-spreading virus. Sydney is already in a state of lockdown till July 9.

With the vaccine chaos overtaking several states, Omar Khorshid, the president of the Australian Medical Association said: "AstraZeneca is safe, it is effective, but for those under 60 there is a better vaccine and that is Pfizer" as three Australian states said they were not consulted before Morrison's announcement.

Australia has vaccinated just 5 per cent of its population but has recorded relatively low 30,500 coronavirus cases and 910 deaths but has witnessed a surge in cases in the past month worrying health officials.

(With inputs from Agencies)

After Australian PM Scott Morrison allowed citizens under 40 to get the AstraZeneca vaccine several state governments resisted the central governments call to vaccinate people.

After Australian PM Scott Morrison allowed citizens under 40 to get the AstraZeneca vaccine several state governments resisted the central governments call to vaccinate people. Watch: The country's health minister Greg Hunt said that "COVID-19 vaccine AstraZeneca can be used in adults aged under 60 years of age for whom Pfizer is not available," while adding, "The benefits are likely to outweigh the risks for that individual." Thank you Ken and each and every Australian who has received a COVID-19 vaccination. Getting a COVID-19 vaccine protects you & your community. https://t.co/JjYp9GOJIh — Greg Hunt (@GregHuntMP) June 22, 2021 × However, Western Australia's premier Mark McGowan on giving access to those under 40, said: "That shouldn’t happen. Clearly, we get different advice, I suppose, or have a different approach." Australia has now passed 7 million doses of COVID-19 vaccine administered. Thank you to each and every Australian who has come forward for their vaccination. You are helping to save lives and protect lives. pic.twitter.com/nZFvwd0lND — Greg Hunt (@GregHuntMP) June 25, 2021 × The hesitancy over AstraZeneca shots is linked to reports of blood clots even as the World Health Organization(WHO) recommended continued use of the AstraZeneca shot asserting that benefits outweighed the rare risk of clots. "Now the ATAGI (Australian Technical Advisory Group on Immunisation) advice talks about a preference for AstraZeneca to be available, made available to those as preferred for those over 60," the Australian PM had said. "But the advice does not preclude persons under 60 from getting the AstraZeneca vaccine," Morrison added. Morrison had said that all under-60s should “go and have that discussion with your GP” over AstraZeneca vaccine shots. Australia’s High Commissioner to India, Barry O’Farrell took the second shot of the AstraZeneca(Covishield) while saying on Twitter, "thought it fitting to wear my NSW Blues jersey." Second Astra Zeneca shot (Covishield) courtesy of the Govt of India 🇮🇳. Thought it fitting to wear my ⁦@NSWBlues⁩ jersey #TwoWinsTwoShots. pic.twitter.com/yZR7Z2cx5b — Barry O'Farrell (@barryofarrell) June 29, 2021 × The Australian PM had said that the Delta variant was proving "to be a far more difficult element" and presenting "very different challenges". Several million Australians are in various forms of lockdown amid a slow vaccine rollout. Morrison said young people can take the vaccine after talking to the doctor who will be covered by a no-fault indemnity scheme. Amid the vaccine row, Northern Queensland state along with the Western Australian capital of Perth announced lockdowns to combat the fast-spreading virus. Sydney is already in a state of lockdown till July 9. With the vaccine chaos overtaking several states, Omar Khorshid, the president of the Australian Medical Association said: "AstraZeneca is safe, it is effective, but for those under 60 there is a better vaccine and that is Pfizer" as three Australian states said they were not consulted before Morrison's announcement. Australia has vaccinated just 5 per cent of its population but has recorded relatively low 30,500 coronavirus cases and 910 deaths but has witnessed a surge in cases in the past month worrying health officials. (With inputs from Agencies)

Australia faces AstraZeneca vaccine chaos over PM Morrison's statement

In a fresh blow to Australia's already inadequate vaccine rollout, the country has recommended that&nbsp;AstraZeneca's <a href="https://www.wionews.com/topics/coronavirus-vaccine">coronavirus vaccine</a> should not be given to people under 60.

The reason behind this decision is concerns over possible links between the vaccine and blood clots. According to Health Minister Greg Hunt, this means that Pfizer is now "the preferred vaccine" for everyone under 60 years old.

Back in April, Australian authorities had already restricted the&nbsp;AstraZeneca&nbsp;shot to those over 50 after several cases of severe blood clots were possibly linked to it. This fresh restriction comes following the death of a 52-year-old woman, who died of blood clotting after receiving the jab.

Also read |&nbsp;<a href="https://www.wionews.com/world/eu-adds-another-rare-blood-condition-as-side-effect-of-astrazeneca-shot-390914">EU adds another rare blood condition as side effect of AstraZeneca shot</a>

Hunt admitted the move would "challenge" the country's already badly stalled vaccine rollout, which has seen just three per cent of its population of 25 million fully inoculated so far.

On Thursday, the conservative government also announced that a senior army officer, Lieutenant General John Frewen, would be spearheading the federal vaccine rollout operation “Vaccine Shield”. This comes amid facing growing public disquiet over the slow rate of jabs.

With inoculations now the responsibility of Australian states, this move is likely to have a marginal impact at best.

Also read |&nbsp;<a href="https://www.wionews.com/world/european-medicines-agency-official-suggests-ditching-astrazeneca-jab-391169">European Medicines Agency official suggests ditching AstraZeneca jab</a>&nbsp;

Australia has made heavy investments in the&nbsp;AstraZeneca&nbsp;vaccine, even developing a facility to produce 50 million doses locally.

In comparison, purchases of other shots have been more limited and have faced multiple delays, something that has forced the government to abandon its target of vaccinating all adults by September this year.

Australia has witnessed only a few locally transmitted <a href="https://www.wionews.com/topics/coronavirus">COVID-19</a> cases.

Also read |&nbsp;<a href="https://www.wionews.com/science/astrazenecas-antibody-fails-in-protecting-exposed-patients-from-covid-19-391632">AstraZeneca's antibody fails in protecting exposed patients from COVID-19</a>

The country had previously closed its borders to all but a handful of foreign travellers, and these measures are expected to stay in place until a large percentage of Australia’s adults are vaccinated.

The virus, in the meantime, has repeatedly jumped from hotel quarantine facilities into the community, sparking lockdowns and costly restrictions.

One of the most populous cities of Australia Melbourne has exited its fourth lockdown just last week and&nbsp;Sydney is now on high alert after a cluster of three cases emerged linked to a foreign aircrew shuttle driver.

Several venues around the famed Bondi beach have been labelled potential virus hotspots, with anyone visiting told to get tested and stay at home for two weeks.

In a fresh blow to Australia's already inadequate vaccine rollout, the country has recommended that AstraZeneca's coronavirus vaccine should not be given to people under 60.

In a fresh blow to Australia's already inadequate vaccine rollout, the country has recommended that AstraZeneca's coronavirus vaccine should not be given to people under 60. The reason behind this decision is concerns over possible links between the vaccine and blood clots. According to Health Minister Greg Hunt, this means that Pfizer is now "the preferred vaccine" for everyone under 60 years old. Back in April, Australian authorities had already restricted the AstraZeneca shot to those over 50 after several cases of severe blood clots were possibly linked to it. This fresh restriction comes following the death of a 52-year-old woman, who died of blood clotting after receiving the jab. Also read | EU adds another rare blood condition as side effect of AstraZeneca shot Hunt admitted the move would "challenge" the country's already badly stalled vaccine rollout, which has seen just three per cent of its population of 25 million fully inoculated so far. On Thursday, the conservative government also announced that a senior army officer, Lieutenant General John Frewen, would be spearheading the federal vaccine rollout operation “Vaccine Shield”. This comes amid facing growing public disquiet over the slow rate of jabs. With inoculations now the responsibility of Australian states, this move is likely to have a marginal impact at best. Also read | European Medicines Agency official suggests ditching AstraZeneca jab Australia has made heavy investments in the AstraZeneca vaccine, even developing a facility to produce 50 million doses locally. In comparison, purchases of other shots have been more limited and have faced multiple delays, something that has forced the government to abandon its target of vaccinating all adults by September this year. Australia has witnessed only a few locally transmitted COVID-19 cases. Also read | AstraZeneca's antibody fails in protecting exposed patients from COVID-19 The country had previously closed its borders to all but a handful of foreign travellers, and these measures are expected to stay in place until a large percentage of Australia’s adults are vaccinated. The virus, in the meantime, has repeatedly jumped from hotel quarantine facilities into the community, sparking lockdowns and costly restrictions. One of the most populous cities of Australia Melbourne has exited its fourth lockdown just last week and Sydney is now on high alert after a cluster of three cases emerged linked to a foreign aircrew shuttle driver. Several venues around the famed Bondi beach have been labelled potential virus hotspots, with anyone visiting told to get tested and stay at home for two weeks.

Amid fears of blood clots, Australia further restricts AstraZeneca vaccine

Adding to the fear of side-effects of the AstraZeneca vaccine, Australia has reported a woman’s death which might be a result of the vaccine.

A 52-year-old woman from New South Wales died after getting a shot of the AstraZeneca vaccine against <a href="https://www.wionews.com/topics/coronavirus">coronavirus</a>. The woman was suffering from a severe kind of blood clotting after the vaccine dose, which had caused a "blood clot in the brain known as a cerebral venous sinus thrombosis".

Also read |&nbsp;<a href="https://www.wionews.com/india-news/scientists-find-new-coronavirus-variant-in-india-which-causes-severe-pneumonia-pathological-changes-in-lungs-390159">Scientists find new coronavirus variant in India which causes severe pneumonia, 'pathological changes in lungs'</a>

This is the second case in Australia that is being linked to the AstraZeneca vaccine and experts believe the receivers of the vaccine may develop a rare condition known as thrombosis with thrombocytopenia syndrome (TTS).

Australia’s first death due to blood clotting happened in April, and since then the local physicians have studied several cases from around the world to get more information about this rare condition.

Have a look |&nbsp;<a href="https://www.wionews.com/photos/explained-european-covid-19-travel-certificate-us-considers-own-vaccine-passport-390357" hreflang="en">Explained: European COVID-19 travel certificate; US considers own vaccine&nbsp;passport</a>

"The treatment for it is very well established and it is not something that always kills the patient," said Dr Indu Singh, an associate professor of haematology at Griffith University. "We know what to look for, and as long as we know about it, we are aware of it, it’s treatable, and the treatment is advanced."

Till now, Australia has reported 35 confirmed cases of TTS, out of which 31 have been discharged from the hospital and the remaining, are receiving treatment.

"I will point out it is only the second death, with now over 3.6m doses of this vaccine being given across Australia," Australia’s chief medical officer, Prof Paul Kelly said in a statement. "This remains an extremely rare event to get these serious clots, but when they happen, as we have seen in this case, it can have tragic circumstances. My heart goes out to the family and all the friends and colleagues of this particular person."

Adding to the fear of side-effects of the AstraZeneca vaccine, Australia has reported a woman’s death which might be a result of the vaccine. A 52-year-old woman from New South Wales died after getting a shot of the AstraZeneca vaccine against coronavirus.

Adding to the fear of side-effects of the AstraZeneca vaccine, Australia has reported a woman’s death which might be a result of the vaccine. A 52-year-old woman from New South Wales died after getting a shot of the AstraZeneca vaccine against coronavirus. The woman was suffering from a severe kind of blood clotting after the vaccine dose, which had caused a "blood clot in the brain known as a cerebral venous sinus thrombosis". Also read | Scientists find new coronavirus variant in India which causes severe pneumonia, 'pathological changes in lungs' This is the second case in Australia that is being linked to the AstraZeneca vaccine and experts believe the receivers of the vaccine may develop a rare condition known as thrombosis with thrombocytopenia syndrome (TTS). Australia’s first death due to blood clotting happened in April, and since then the local physicians have studied several cases from around the world to get more information about this rare condition. Have a look | Explained: European COVID-19 travel certificate; US considers own vaccine passport "The treatment for it is very well established and it is not something that always kills the patient," said Dr Indu Singh, an associate professor of haematology at Griffith University. "We know what to look for, and as long as we know about it, we are aware of it, it’s treatable, and the treatment is advanced." Till now, Australia has reported 35 confirmed cases of TTS, out of which 31 have been discharged from the hospital and the remaining, are receiving treatment. "I will point out it is only the second death, with now over 3.6m doses of this vaccine being given across Australia," Australia’s chief medical officer, Prof Paul Kelly said in a statement. "This remains an extremely rare event to get these serious clots, but when they happen, as we have seen in this case, it can have tragic circumstances. My heart goes out to the family and all the friends and colleagues of this particular person."

Australia reports second death 'possibly' due to blood clots after AstraZeneca shot

Denmark on Tuesday banned the use of Oxford-AstraZeneca <a href="https://www.wionews.com/topics/coronavirus-vaccine">coronavirus vaccine</a>, becoming the first European nation to take such action over rare but serious suspected health risks.&nbsp;

"Denmark's vaccination campaign will go ahead without the AstraZeneca vaccine," Danish Health Authority director Soren Brostrom in a press conference was quoted as saying by news agency AFP.&nbsp;

Watch |&nbsp;

<div class="videoWrapper trancodeVideo"><iframe allowfullscreen="" autoplay="1" class="includeVideo" frameborder="0" height="350" src="https://www.wionews.com/videos/study-finds-inactive-people-more-likely-to-die-of-covid-19-377530/embed" style="width:100%;max-width:560px;" width="560"></iframe></div>

The decision comes as Germany announced that people aged under 60 who had received the first dose of AstraZeneca jab will receive a different Covid-19 vaccine for their second dose.&nbsp;

Among millions of doses of AstraZeneca vaccine that have been administered, there have been a few blood clot cases and the World Health Organization and the European Medicines Agency (EMA) have shrugged off fears related to the vaccine.&nbsp;

The clots appear in veins in the brain, known as cerebral venous sinus thrombosis, CVST, as well as in the abdomen and arteries.&nbsp;

Also read | <a href="https://www.wionews.com/science/covid-19-virus-can-sustain-itself-for-up-to-a-month-in-dust-study-377452">COVID-19 virus can sustain itself for up to a month in dust: Study</a>

According to the EMA, 222 cases of atypical thromboses have been detected out of 34 million AstraZeneca doses in European Economic Area (EU, Iceland, Norway, Liechtenstein) and Britain, as of April 4.

There have been 18 deaths too according to this condition as of March 22.&nbsp;

Meanwhile, South Africa has suspended the use of Johnson &amp; Johnson vaccine over potential blood clot risks reported by the US, the health minister said.

(With inputs from agencies)

Denmark on Tuesday banned the use of Oxford-AstraZeneca coronavirus vaccine, becoming the first European nation to take such action over rare but serious suspected health risks.

Denmark on Tuesday banned the use of Oxford-AstraZeneca coronavirus vaccine, becoming the first European nation to take such action over rare but serious suspected health risks. "Denmark's vaccination campaign will go ahead without the AstraZeneca vaccine," Danish Health Authority director Soren Brostrom in a press conference was quoted as saying by news agency AFP. Watch | The decision comes as Germany announced that people aged under 60 who had received the first dose of AstraZeneca jab will receive a different Covid-19 vaccine for their second dose. Among millions of doses of AstraZeneca vaccine that have been administered, there have been a few blood clot cases and the World Health Organization and the European Medicines Agency (EMA) have shrugged off fears related to the vaccine. The clots appear in veins in the brain, known as cerebral venous sinus thrombosis, CVST, as well as in the abdomen and arteries. Also read | COVID-19 virus can sustain itself for up to a month in dust: Study According to the EMA, 222 cases of atypical thromboses have been detected out of 34 million AstraZeneca doses in European Economic Area (EU, Iceland, Norway, Liechtenstein) and Britain, as of April 4. There have been 18 deaths too according to this condition as of March 22. Meanwhile, South Africa has suspended the use of Johnson & Johnson vaccine over potential blood clot risks reported by the US, the health minister said. (With inputs from agencies)

Denmark becomes first European nation to stop using AstraZeneca vaccine

The Food and Drug Administration of the US government said on Tuesday it is asking states to temporarily halt using Johnson &amp; Johnson’s Covid-19 vaccine after six people in the country developed a rare blood clotting disorder. 
 
Also Read |&nbsp;<a href="https://www.wionews.com/world/dont-ignore-these-new-oral-symptoms-of-covid-19-377054">Don't ignore these new oral symptoms of Covid-19</a>

"Today FDA and @CDCgov issued a statement regarding the Johnson &amp; Johnson #COVID19 vaccine. We are recommending a pause in the use of this vaccine out of an abundance of caution. As of 4/12, 6.8m+ doses of the J&amp;J vaccine have been administered in the U.S. CDC &amp; FDA are reviewing data involving 6 reported U.S. cases of a rare &amp; severe type of blood clot in individuals after receiving the vaccine. Right now, these adverse events appear to be extremely rare," tweeted the US FDA.

<div class="ui-state-default" contenteditable="false">
<div class="twitter-block" draggable="false">
<blockquote class="twitter-tweet">
As of 4/12, 6.8m+ doses of the J&amp;J vaccine have been administered in the U.S. CDC &amp; FDA are reviewing data involving 6 reported U.S. cases of a rare &amp; severe type of blood clot in individuals after receiving the vaccine. Right now, these adverse events appear to be extremely rare
— U.S. FDA (@US_FDA) <a href="https://twitter.com/US_FDA/status/1381925613691412480?ref_src=twsrc%5Etfw">April 13, 2021</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
<a class="close-mark close-div" href="#" id="jqclosemark">×</a></div>

“COVID-19 vaccine safety is a top priority for the federal government, and we take all reports of health problems following COVID-19 vaccination very seriously,” the FDA said in a joint statement with the Centers for Disease Control and Prevention. 
 
Also Read |&nbsp;<a href="https://www.wionews.com/science/these-are-the-three-new-symptoms-of-covid-19-dont-take-them-lightly-375900">These are the three new symptoms of COVID-19. Don't take them lightly</a>

“People who have received the J&amp;J vaccine who develop a severe headache, abdominal pain, leg pain, or shortness of breath within three weeks after vaccination should contact their health care provider,” the FDA and CDC said.

Meanwhile, the Australian government has also decided against buying the single-dose Johnson &amp; Johnson coronavirus vaccine as a way to accelerate its immunisation programme.

Health Minister Greg Hunt said on Tuesday the Johnson &amp; Johnson vaccine is similar to the AstraZeneca&nbsp; product, which Australia already contracted to buy.

(With inputs from agencies)

The Food and Drug Administration of the US government said on Tuesday it is asking states to temporarily halt using Johnson & Johnson’s Covid-19 vaccine after six people in the country developed a rare blood clotting disorder.

The Food and Drug Administration of the US government said on Tuesday it is asking states to temporarily halt using Johnson & Johnson’s Covid-19 vaccine after six people in the country developed a rare blood clotting disorder. Also Read | Don't ignore these new oral symptoms of Covid-19 "Today FDA and @CDCgov issued a statement regarding the Johnson & Johnson #COVID19 vaccine. We are recommending a pause in the use of this vaccine out of an abundance of caution. As of 4/12, 6.8m+ doses of the J&J vaccine have been administered in the U.S. CDC & FDA are reviewing data involving 6 reported U.S. cases of a rare & severe type of blood clot in individuals after receiving the vaccine. Right now, these adverse events appear to be extremely rare," tweeted the US FDA. As of 4/12, 6.8m+ doses of the J&J vaccine have been administered in the U.S. CDC & FDA are reviewing data involving 6 reported U.S. cases of a rare & severe type of blood clot in individuals after receiving the vaccine. Right now, these adverse events appear to be extremely rare — U.S. FDA (@US_FDA) April 13, 2021 × “COVID-19 vaccine safety is a top priority for the federal government, and we take all reports of health problems following COVID-19 vaccination very seriously,” the FDA said in a joint statement with the Centers for Disease Control and Prevention. Also Read | These are the three new symptoms of COVID-19. Don't take them lightly “People who have received the J&J vaccine who develop a severe headache, abdominal pain, leg pain, or shortness of breath within three weeks after vaccination should contact their health care provider,” the FDA and CDC said. Meanwhile, the Australian government has also decided against buying the single-dose Johnson & Johnson coronavirus vaccine as a way to accelerate its immunisation programme. Health Minister Greg Hunt said on Tuesday the Johnson & Johnson vaccine is similar to the AstraZeneca product, which Australia already contracted to buy. (With inputs from agencies)

US halts use of Johnson & Johnson vaccine due to rare blood clotting issues

Australia has halted the use of the AstraZeneca COVID-19 vaccine for younger people over blood clots concerns. Officials said the AstraZeneca shot should no longer be given to people under the age of 50, unless they had already received a first dose without any ill effects.

Australia halts AstraZeneca COVID-19 vaccine for under 50s

Portugal has restricted the use of the AstraZeneca COVID-19 vaccine to people above the age of 60. Country's coordinator of the national task force for vaccination against COVID-19 Henrique Gouveia e Melo, said that this will have a "small impact," on the vaccination rollout plans.

Portugal restricts the use of AstraZeneca COVID-19 vaccine

Europe’s drug regulator has denied establishing a causal connection between the AstraZeneca <a href="https://www.wionews.com/topics/coronavirus-vaccine">coronavirus vaccine</a> and the formation of blood clots.

A little after a senior official claimed that the European Medicines Agency (EMA) had already established a link between the AstraZeneca-Oxford jab and a rare blood clotting syndrome, the regulator has backtracked on the official’s statement and has said that it has “not yet reached a conclusion and the review is currently ongoing”.

Also read |&nbsp;<a href="https://www.wionews.com/world/saudi-arabia-to-allow-only-immunised-pilgrims-to-mecca-375572" hreflang="en">Saudi Arabia to allow only 'immunised' pilgrims to Mecca</a>

EMA’s head of vaccines, Marco Cavaleri, had earlier told a local Italian newspaper that “it is clear there is a link with the vaccine … But we still do not know what causes this reaction”.

The clash of statements has come after a few European countries temporarily suspended the use of the AstraZeneca vaccine as many suspected the formation of blood clots in the people who got the jab.

Also read |&nbsp;<a href="https://www.wionews.com/world/now-singapore-set-to-accept-coronavirus-digital-passport-375533" hreflang="en">Now, Singapore set to accept coronavirus digital passport</a>

However, the EMA had denied these reports and reiterated that the vaccine is safe and effective. It also added that it could, however, not completely rule out the possibility and thus would continue to investigate.

The regulator and other experts have asked people to continue taking the vaccine till the investigation is completed as the benefits have outweighed the possibility of danger, till now.

Also read |&nbsp;<a href="https://www.wionews.com/world/why-thailand-is-prioritising-phuket-for-early-coronavirus-vaccine-rollout-375480" hreflang="en">Why Thailand is prioritising Phuket for early coronavirus vaccine rollout</a>

For now, the EMA is investigating the death of 14 people who developed cerebral venous sinus thrombosis (CVST) after getting a shot of the AstraZeneca vaccine around March 22 and lost their lives to it.

“We are trying to get a precise picture of what is happening, to define in detail this syndrome due to the vaccine,” Cavaleri told the Italian newspaper. “Among the vaccinated, there are more cases of cerebral thrombosis … among young people than we would expect.”

Europe’s drug regulator has denied establishing a causal connection between the AstraZeneca coronavirus vaccine and the formation of blood clots. A little after a senior official claimed that the European Medicines Agency (EMA) had already established a link between the AstraZeneca-Oxford jab and a rare blood clotting syndrome, the regulator has backtracked on the official’s statement and has said that it has “not yet reached a conclusion and the review is currently ongoing”.

Europe’s drug regulator has denied establishing a causal connection between the AstraZeneca coronavirus vaccine and the formation of blood clots. A little after a senior official claimed that the European Medicines Agency (EMA) had already established a link between the AstraZeneca-Oxford jab and a rare blood clotting syndrome, the regulator has backtracked on the official’s statement and has said that it has “not yet reached a conclusion and the review is currently ongoing”. Also read | Saudi Arabia to allow only 'immunised' pilgrims to Mecca EMA’s head of vaccines, Marco Cavaleri, had earlier told a local Italian newspaper that “it is clear there is a link with the vaccine … But we still do not know what causes this reaction”. The clash of statements has come after a few European countries temporarily suspended the use of the AstraZeneca vaccine as many suspected the formation of blood clots in the people who got the jab. Also read | Now, Singapore set to accept coronavirus digital passport However, the EMA had denied these reports and reiterated that the vaccine is safe and effective. It also added that it could, however, not completely rule out the possibility and thus would continue to investigate. The regulator and other experts have asked people to continue taking the vaccine till the investigation is completed as the benefits have outweighed the possibility of danger, till now. Also read | Why Thailand is prioritising Phuket for early coronavirus vaccine rollout For now, the EMA is investigating the death of 14 people who developed cerebral venous sinus thrombosis (CVST) after getting a shot of the AstraZeneca vaccine around March 22 and lost their lives to it. “We are trying to get a precise picture of what is happening, to define in detail this syndrome due to the vaccine,” Cavaleri told the Italian newspaper. “Among the vaccinated, there are more cases of cerebral thrombosis … among young people than we would expect.”

EU drug regulator says it hasn't found causal link between AstraZeneca and blood clots

The European Union drug regulator said on Wednesday that it has not identified any "specific risk factors" of the Oxford-AstraZeneca <a href="https://www.wionews.com/topics/coronavirus-vaccine">coronavirus&nbsp;vaccine</a>, but is carrying out further analysis.&nbsp;

"At present, the review has not identified any specific risk factors, such as age, gender or a previous medical history of clotting disorders, for these very rare events," the European Medicines Agency in a statement said.&nbsp;

Watch |&nbsp;

<div class="videoWrapper trancodeVideo"><iframe allowfullscreen="" autoplay="1" class="includeVideo" frameborder="0" height="350" src="https://www.wionews.com/videos/germany-halts-use-of-astrazeneca-covid-19-vaccine-for-under-60s-374492/embed" style="width:100%;max-width:560px;" width="560"></iframe></div>

The announcement comes after some European countries have limited its use only to the elderly population.&nbsp;

The German government on Tuesday said that Oxford-AstraZeneca's vaccine will be used only for over 60-year-olds after the country's regulatory body found "very rare but very serious cases of thrombosis".&nbsp;

Also read | <a href="https://www.wionews.com/science/biontech-pfizer-say-their-covid-19-vaccine-has-100-efficacy-in-12-15-year-olds-374524">BioNTech-Pfizer say their Covid-19 vaccine has 100% efficacy in 12-15 year olds</a>

Der Spiegel magazine on Tuesday reported that Germany's medicines regulator has confirmed 31 cases of blood clots in people vaccinated with the Oxford-AstraZeneca vaccine and nearly all cases were being detected in young and middle-aged women.

Canada on Monday also halted the drug's use for people under-55s "pending further analysis".&nbsp;

In France, the vaccine can only be used by people over 55s and Spain has taken the same measure for those under-65.&nbsp;

Earlier, the World Health Organization (WHO) and the EU's health body both have shrugged off blood clot fears related to the Oxford-AstraZeneca vaccine, calling it safe to use after probes.&nbsp; 
&nbsp;

The European Union drug regulator said on Wednesday that it has not identified any "specific risk factors" of the Oxford-AstraZeneca coronavirus vaccine, but is carrying out further analysis.

The European Union drug regulator said on Wednesday that it has not identified any "specific risk factors" of the Oxford-AstraZeneca coronavirus vaccine, but is carrying out further analysis. "At present, the review has not identified any specific risk factors, such as age, gender or a previous medical history of clotting disorders, for these very rare events," the European Medicines Agency in a statement said. Watch | The announcement comes after some European countries have limited its use only to the elderly population. The German government on Tuesday said that Oxford-AstraZeneca's vaccine will be used only for over 60-year-olds after the country's regulatory body found "very rare but very serious cases of thrombosis". Also read | BioNTech-Pfizer say their Covid-19 vaccine has 100% efficacy in 12-15 year olds Der Spiegel magazine on Tuesday reported that Germany's medicines regulator has confirmed 31 cases of blood clots in people vaccinated with the Oxford-AstraZeneca vaccine and nearly all cases were being detected in young and middle-aged women. Canada on Monday also halted the drug's use for people under-55s "pending further analysis". In France, the vaccine can only be used by people over 55s and Spain has taken the same measure for those under-65. Earlier, the World Health Organization (WHO) and the EU's health body both have shrugged off blood clot fears related to the Oxford-AstraZeneca vaccine, calling it safe to use after probes.

EU says no age-related risk of AstraZeneca vaccine found so far

Denmark on Saturday reported two cases of hospital staff with blood clots and cerebral haemorrhage after receiving the AstraZeneca Covid-19 vaccination.&nbsp;

The Capital Region of Denmark, the authority that runs public hospitals in Copenhagen, said one of the hospital staff had died and both had received the AstraZeneca vaccine less than 14 days before getting ill.&nbsp;

The Danish medicines agency confirmed it had received two 'serious reports', without giving further details.&nbsp;

There were no details of when the hospital staff got ill.&nbsp;

Some countries including Germany and France this week reversed their decision to temporarily pause use of the AstraZeneca vaccine after reports of cases of rare brain blood clots sent scientists and governments scrambling to determine any link.&nbsp;

Denmark, which put use of the vaccine on hold on March 11, has not yet resumed use.&nbsp;

The European Union's drug watchdog said on Thursday, it is still convinced the benefits of the vaccine outweigh the risks following an investigation into reports of blood clots that prompted more than a dozen nations to suspend its use.&nbsp;

European Medicines Agency (EMA) director Emer Cooke said on Thursday, the watchdog could not definitively rule out a link between blood clot incidents and the vaccine in its investigation into 30 cases of a rare blood clotting condition.&nbsp;

But she said the 'clear' conclusion of the review was that the benefits in protecting people from the risk of death or hospitalisation outweighs the possible risks. The issue deserves further analysis, the EMA said.&nbsp;

AstraZeneca, which developed the shot with Oxford University, has said a review covering more than 17 million people, who had received its shots in the EU and Britain had found no evidence of an increased risk of blood clots.&nbsp;

(With inputs from agencies)&nbsp;

Denmark on Saturday reported two cases of hospital staff with blood clots and cerebral haemorrhage after receiving the AstraZeneca Covid-19 vaccination. The Capital Region of Denmark, the authority that runs public hospitals in Copenhagen, said one of the hospital staff had died and both had received the AstraZeneca vaccine less than 14 days before getting ill.

Denmark on Saturday reported two cases of hospital staff with blood clots and cerebral haemorrhage after receiving the AstraZeneca Covid-19 vaccination. The Capital Region of Denmark, the authority that runs public hospitals in Copenhagen, said one of the hospital staff had died and both had received the AstraZeneca vaccine less than 14 days before getting ill. The Danish medicines agency confirmed it had received two 'serious reports', without giving further details. There were no details of when the hospital staff got ill. Some countries including Germany and France this week reversed their decision to temporarily pause use of the AstraZeneca vaccine after reports of cases of rare brain blood clots sent scientists and governments scrambling to determine any link. Denmark, which put use of the vaccine on hold on March 11, has not yet resumed use. The European Union's drug watchdog said on Thursday, it is still convinced the benefits of the vaccine outweigh the risks following an investigation into reports of blood clots that prompted more than a dozen nations to suspend its use. European Medicines Agency (EMA) director Emer Cooke said on Thursday, the watchdog could not definitively rule out a link between blood clot incidents and the vaccine in its investigation into 30 cases of a rare blood clotting condition. But she said the 'clear' conclusion of the review was that the benefits in protecting people from the risk of death or hospitalisation outweighs the possible risks. The issue deserves further analysis, the EMA said. AstraZeneca, which developed the shot with Oxford University, has said a review covering more than 17 million people, who had received its shots in the EU and Britain had found no evidence of an increased risk of blood clots. (With inputs from agencies)

Two cases of blood clots reported after AstraZeneca shot in Denmark 

EU health regulator on Thursday said that 'no evidence'&nbsp;was found of any direct links between either AstraZeneca or Pfizer Covid vaccine and blood clots.

"The committee has come to a clear scientific conclusion: this is a safe and effective vaccine," European Medicines Agency (EMA) chief Emer Cooke told a press conference after an investigation.

The remarks by the EMA&nbsp;come after the UK health regulator on Thursday also shrugged off concerns regarding Pfizer and Oxford <a href="https://www.wionews.com/topics/coronavirus-vaccine">coronavirus vaccines</a>.&nbsp;&nbsp;

Britain's health regulator on Thursday said it had found no evidence between Oxford-AstraZeneca's&nbsp;coronavirus vaccine&nbsp;and cases of blood clots after several countries halted the use of its jabs over safety fears.&nbsp;

The Medicines and Healthcare products Regulatory Agency (MHRA) also said that they did not find any relation even between Pfizer-BioNTech's vaccine and blood clots.&nbsp;

"There is no evidence that blood clots in veins is occurring more than would be expected in the absence of vaccination, for either vaccine," said June Raine, chief executive of the independent MHRA, as quoted by news agency AFP.&nbsp;

Watch |&nbsp;

<div class="videoWrapper trancodeVideo"><iframe allowfullscreen="" autoplay="1" class="includeVideo" frameborder="0" height="350" src="https://www.wionews.com/videos/india-astrazeneca-vaccinations-will-go-on-with-full-vigour-371400/embed" style="width:100%;max-width:560px;" width="560"></iframe></div>

Earlier, the European Medicines Agency (EMA), has said that it had detected "no indication" of a major problem and the number of clots after receiving the AstraZeneca shot is not higher than the group of people who are unvaccinated.&nbsp;

Also read | <a href="https://www.wionews.com/world/trust-in-astrazeneca-vaccine-is-shaken-in-europe-371386">Trust in AstraZeneca vaccine is shaken in Europe</a>

Meanwhile, the World Health Organization (WHO) on Thursday continued to urge nations to use the Oxford jab.&nbsp;

"The WHO Global Advisory Committee on Vaccine Safety is carefully assessing the latest available safety data," the WHO said in a statement on Wednesday. 
&nbsp;

EU health regulator on Thursday said that 'no evidence' was found of any direct links between either AstraZeneca or Pfizer Covid vaccine and blood clots. "The committee has come to a clear scientific conclusion: this is a safe and effective vaccine," European Medicines Agency (EMA) chief Emer Cooke told a press conference after an investigation.

EU health regulator on Thursday said that 'no evidence' was found of any direct links between either AstraZeneca or Pfizer Covid vaccine and blood clots. "The committee has come to a clear scientific conclusion: this is a safe and effective vaccine," European Medicines Agency (EMA) chief Emer Cooke told a press conference after an investigation. The remarks by the EMA come after the UK health regulator on Thursday also shrugged off concerns regarding Pfizer and Oxford coronavirus vaccines. Britain's health regulator on Thursday said it had found no evidence between Oxford-AstraZeneca's coronavirus vaccine and cases of blood clots after several countries halted the use of its jabs over safety fears. The Medicines and Healthcare products Regulatory Agency (MHRA) also said that they did not find any relation even between Pfizer-BioNTech's vaccine and blood clots. "There is no evidence that blood clots in veins is occurring more than would be expected in the absence of vaccination, for either vaccine," said June Raine, chief executive of the independent MHRA, as quoted by news agency AFP. Watch | Earlier, the European Medicines Agency (EMA), has said that it had detected "no indication" of a major problem and the number of clots after receiving the AstraZeneca shot is not higher than the group of people who are unvaccinated. Also read | Trust in AstraZeneca vaccine is shaken in Europe Meanwhile, the World Health Organization (WHO) on Thursday continued to urge nations to use the Oxford jab. "The WHO Global Advisory Committee on Vaccine Safety is carefully assessing the latest available safety data," the WHO said in a statement on Wednesday.

EU, UK regulator shrug off AstraZeneca vaccine concerns

More than 70 countries have authorised the Oxford- AstraZeneca vaccine and 350 million doses have been doled out across the world. Seventeen million people have been vaccinated in the European Union and UK.

But several countries, starting with Denmark last week, have temporarily halted the use of the AstraZeneca vaccine in recent days to investigate cases of blood clots that occurred after vaccination. They include Italy, Germany, France, Ireland, Thailand, the Netherlands, Norway, Iceland, Congo and Bulgaria.

The number of blood clot cases in vaccinated people is no higher than that seen in the general population.

Blood clots can travel through the body and cause heart attacks, strokes and deadly blockages in the lungs. There are primarily two types of blood clots that are being reported.

The first is deep vein thrombosis (DVT), a condition when blood clots form in a vein located deep inside your body. It usually occurs in the thigh or lower leg. It is most commonly seen in people above 50 years of age and can enhance the chances of developing a pulmonary embolism.

The second type is pulmonary embolism&nbsp;is much more severe. It is a blockage in one of the pulmonary arteries in your lungs. It restricts blood flow and decreases oxygen levels and in most cases, it proves to be fatal.

So far across the EU and UK, there have been 15 events of deep vein thrombosis (DVT) or thrombocytopenia and 22 events of pulmonary embolism reported among those given the vaccine.

According to the European Medicines Agency, there is currently no indication that vaccination had caused these conditions. There’s not much information on the existence of co-morbidities in these patients either. But a few adverse reactions have raised questions and&nbsp;concerns.

Meanwhile, the World Health Organization appealed to countries not to pause vaccination campaigns after a few European nations and one in Asia joined handfuls that have suspended the use of AstraZeneca's Covid-19 vaccine over safety fears.

The WHO said its advisory panel was reviewing reports related to the shot and would release its findings as soon as possible. But it said it was unlikely to change its recommendations, issued last month, for widespread use, including in countries where the South African variant of the virus may reduce its efficacy.

"It's very important to understand that, yes,&nbsp;we should continue using the AstraZeneca vaccine. All that we're looking at is what we always look at: any safety signal must be investigated. In fact, it is very important that we are hearing safety signals because if we were not hearing about any safety signals, then that would suggest there is not enough review and vigilance. We must always ensure we look for any safety signals when we roll out vaccines and we must review them. But there is no indication to not use it,” WHO spokeswoman Margaret Harris said.

But even after this statement, not everybody is convinced.

At least 16 countries have placed a temporary suspension on the vaccine and more countries may follow suit.

AstraZeneca's shot was among the first and cheapest to be developed and launched at volume since the coronavirus was first identified in central China at the end of 2019 and is set to be the mainstay of vaccination programmes in much of the developing world. The virus has killed more than 2.7 million people.

(With inputs from agencies)

More than 70 countries have authorised the Oxford- AstraZeneca vaccine and 350 million doses have been doled out across the world. Seventeen million people have been vaccinated in the European Union and UK.

More than 70 countries have authorised the Oxford- AstraZeneca vaccine and 350 million doses have been doled out across the world. Seventeen million people have been vaccinated in the European Union and UK. But several countries, starting with Denmark last week, have temporarily halted the use of the AstraZeneca vaccine in recent days to investigate cases of blood clots that occurred after vaccination. They include Italy, Germany, France, Ireland, Thailand, the Netherlands, Norway, Iceland, Congo and Bulgaria. The number of blood clot cases in vaccinated people is no higher than that seen in the general population. Blood clots can travel through the body and cause heart attacks, strokes and deadly blockages in the lungs. There are primarily two types of blood clots that are being reported. The first is deep vein thrombosis (DVT), a condition when blood clots form in a vein located deep inside your body. It usually occurs in the thigh or lower leg. It is most commonly seen in people above 50 years of age and can enhance the chances of developing a pulmonary embolism. The second type is pulmonary embolism is much more severe. It is a blockage in one of the pulmonary arteries in your lungs. It restricts blood flow and decreases oxygen levels and in most cases, it proves to be fatal. So far across the EU and UK, there have been 15 events of deep vein thrombosis (DVT) or thrombocytopenia and 22 events of pulmonary embolism reported among those given the vaccine. According to the European Medicines Agency, there is currently no indication that vaccination had caused these conditions. There’s not much information on the existence of co-morbidities in these patients either. But a few adverse reactions have raised questions and concerns. Meanwhile, the World Health Organization appealed to countries not to pause vaccination campaigns after a few European nations and one in Asia joined handfuls that have suspended the use of AstraZeneca's Covid-19 vaccine over safety fears. The WHO said its advisory panel was reviewing reports related to the shot and would release its findings as soon as possible. But it said it was unlikely to change its recommendations, issued last month, for widespread use, including in countries where the South African variant of the virus may reduce its efficacy. "It's very important to understand that, yes, we should continue using the AstraZeneca vaccine. All that we're looking at is what we always look at: any safety signal must be investigated. In fact, it is very important that we are hearing safety signals because if we were not hearing about any safety signals, then that would suggest there is not enough review and vigilance. We must always ensure we look for any safety signals when we roll out vaccines and we must review them. But there is no indication to not use it,” WHO spokeswoman Margaret Harris said. But even after this statement, not everybody is convinced. At least 16 countries have placed a temporary suspension on the vaccine and more countries may follow suit. AstraZeneca's shot was among the first and cheapest to be developed and launched at volume since the coronavirus was first identified in central China at the end of 2019 and is set to be the mainstay of vaccination programmes in much of the developing world. The virus has killed more than 2.7 million people. (With inputs from agencies)

Several countries halt AstraZeneca jab: Does the vaccine cause blood clots?

France, Italy and Germany became the latest major European countries to block Astrazeneca's Covid-19 vaccines over reports of dangerous blood clots in some recipients.

News Alert: Italy, Germany, France suspends AstraZeneca jabs

After several Nordic nations suspended the use of Oxford-AstraZeneca's <a href="https://www.wionews.com/topics/coronavirus-vaccine">coronavirus vaccine</a>, the European Union's drug regulator advised European countries to keep using the jabs during a probe of blood clots cases.&nbsp;

"The position of EMA's safety committee... is that the vaccine's benefits continue to outweigh its risks and the vaccine can continue to be administered while investigation of cases of thromboembolic events is ongoing," European Medicines Agency (EMA) in a statement said.&nbsp;

Watch |&nbsp;

<div class="videoWrapper trancodeVideo"><iframe allowfullscreen="" autoplay="1" class="includeVideo" frameborder="0" height="350" src="https://www.wionews.com/videos/astrazeneca-vaccine-effective-against-brazil-variant-study-368333/embed" style="width:100%;max-width:560px;" width="560"></iframe></div>

"There is currently no indication that vaccination has caused these conditions, which are not listed as side effects with this vaccine."

The regulator's assurance comes after the United Kingdom defended Oxford's vaccine, saying it's "safe and effective".&nbsp;

"We've been clear that it's both safe and effective... and when people are asked to come forward and take it, they should do so in confidence," PM Boris Johnson's spokesman told reporters.

Also read | <a href="https://www.wionews.com/world/denmark-suspends-use-of-astrazeneca-covid-vaccine-due-to-blood-clot-fears-369692">Denmark, Norway suspend use of AstraZeneca COVID vaccine due to blood clot fears</a>

He also said that country's vaccine programme results have lowered the number of Covid-19 cases, hospitalisations, and deaths, suggesting that the vaccine is safe.&nbsp;

Denmark, Norway and Iceland on Thursday temporarily paused the use of AstraZeneca's vaccine over cases of patients developing blood clots after receiving jabs.

Amongst the three nations, Denmark was the first to announce the suspension, with the country's health authority saying "serious cases of blood clots" have been detected.

However, it said that the measure is "precautionary" and at the moment it has found no connection between AstraZeneca's jabs and blood clots.

After several Nordic nations suspended the use of Oxford-AstraZeneca's coronavirus vaccine, the European Union's drug regulator advised European countries to keep using the jabs during a probe of blood clots cases.

After several Nordic nations suspended the use of Oxford-AstraZeneca's coronavirus vaccine, the European Union's drug regulator advised European countries to keep using the jabs during a probe of blood clots cases. "The position of EMA's safety committee... is that the vaccine's benefits continue to outweigh its risks and the vaccine can continue to be administered while investigation of cases of thromboembolic events is ongoing," European Medicines Agency (EMA) in a statement said. Watch | "There is currently no indication that vaccination has caused these conditions, which are not listed as side effects with this vaccine." The regulator's assurance comes after the United Kingdom defended Oxford's vaccine, saying it's "safe and effective". "We've been clear that it's both safe and effective... and when people are asked to come forward and take it, they should do so in confidence," PM Boris Johnson's spokesman told reporters. Also read | Denmark, Norway suspend use of AstraZeneca COVID vaccine due to blood clot fears He also said that country's vaccine programme results have lowered the number of Covid-19 cases, hospitalisations, and deaths, suggesting that the vaccine is safe. Denmark, Norway and Iceland on Thursday temporarily paused the use of AstraZeneca's vaccine over cases of patients developing blood clots after receiving jabs. Amongst the three nations, Denmark was the first to announce the suspension, with the country's health authority saying "serious cases of blood clots" have been detected. However, it said that the measure is "precautionary" and at the moment it has found no connection between AstraZeneca's jabs and blood clots.

Oxford-AstraZeneca Covid-19 vaccine can be used until probe results: EU regulator

blood-clots

Blood Clots, News on Blood Clots, stories on Blood Clots, articles on Blood Clots, Blood Clots stories at Wion, Blood Clots news, Blood Clots latest news